Advantage Alpha Capital Partners LP Acquires Shares of 11,336 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Advantage Alpha Capital Partners LP bought a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 11,336 shares of the company's stock, valued at approximately $510,000.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in shares of Protagonist Therapeutics by 749.2% in the third quarter. GAMMA Investing LLC now owns 552 shares of the company's stock valued at $25,000 after purchasing an additional 487 shares during the last quarter. Exchange Traded Concepts LLC bought a new position in Protagonist Therapeutics in the 3rd quarter worth approximately $43,000. Russell Investments Group Ltd. acquired a new position in shares of Protagonist Therapeutics during the first quarter worth approximately $35,000. CWM LLC boosted its position in shares of Protagonist Therapeutics by 910.3% in the third quarter. CWM LLC now owns 1,273 shares of the company's stock valued at $57,000 after acquiring an additional 1,147 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Protagonist Therapeutics in the third quarter valued at approximately $69,000. Institutional investors own 98.63% of the company's stock.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the business's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $46.96, for a total value of $3,687,299.20. Following the transaction, the chief executive officer now owns 435,208 shares of the company's stock, valued at approximately $20,437,367.68. The trade was a 15.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Arturo Md Molina sold 1,906 shares of the firm's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $40.98, for a total value of $78,107.88. Following the completion of the sale, the insider now owns 46,444 shares of the company's stock, valued at approximately $1,903,275.12. This trade represents a 3.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 232,066 shares of company stock valued at $10,681,738. 5.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. StockNews.com upgraded shares of Protagonist Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, August 8th. Wedbush reissued an "outperform" rating and set a $58.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. JMP Securities lowered their price target on Protagonist Therapeutics from $45.00 to $43.00 and set a "market outperform" rating on the stock in a research note on Wednesday, August 7th. Truist Financial began coverage on Protagonist Therapeutics in a research report on Monday, September 9th. They issued a "buy" rating and a $60.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and issued a $50.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Protagonist Therapeutics presently has a consensus rating of "Buy" and an average target price of $53.57.

Protagonist Therapeutics Stock Up 0.3 %

NASDAQ:PTGX traded up $0.12 during trading hours on Wednesday, reaching $44.95. The company had a trading volume of 569,522 shares, compared to its average volume of 750,584. The stock has a 50-day moving average of $45.24 and a two-hundred day moving average of $39.62. Protagonist Therapeutics, Inc. has a one year low of $17.13 and a one year high of $48.89. The firm has a market capitalization of $2.68 billion, a PE ratio of 16.90 and a beta of 2.17.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.